All In Biotech

Drug Trial Radar · NCT04449484

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects With Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Jun 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Aug 4, 2020

Primary completion

Jan 5, 2022

Study completion Jan 5, 2022

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Takeda
First posted
Jun 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled study of multiple ascending iv doses of MEDI341 in male and female subjects with Parkinson's Disease.

Conditions

  • Parkinson's Disease

Interventions

  • MEDI1341Drug

    Intravenous infusion over 60 minutes

  • PlaceboOther

    Intravenous infusion over 60 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 28 weeks
  2. Vital SignsTime frame: 21 weeks
  3. Oral Body TemperatureTime frame: 21 weeks
  4. Body WeightTime frame: 21 weeks
  5. Safety Laboratory TestsTime frame: 21 weeks
  6. ElectrocardiogramsTime frame: 21 weeks
  7. Ophthalmic assessmentsTime frame: 21 weeks
  8. Suicidal IdeationTime frame: 21 weeks
  9. Cognitive impairmentTime frame: 21 weeks
  10. ElectrocardiogramsTime frame: 21 weeks
  11. ElectrocardiogramsTime frame: 21 weeks
  12. ElectrocardiogramsTime frame: 21 weeks
  13. ElectrocardiogramsTime frame: 21 weeks
  14. ElectrocardiogramsTime frame: 21 weeks
  15. ElectrocardiogramsTime frame: 21 weeks
  16. ElectrocardiogramsTime frame: 21 weeks
  17. Suicidal BehaviourTime frame: 21 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Long Beach, California

  • Research Site

    Hallandale, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.